by Gonzalo Payan | Sep 16, 2016
MAX BioPharma has been fortunate to receive support from the National Institutes of Health (NIH) for its research and development activities. MAX BioPharma is pleased to announce that its recent set of Phase 2 SBIR grant applications to the NIH for its Bone Program...by Gonzalo Payan | Aug 13, 2016
MAX BioPharma Announces Key Update on its Oxysterol Therapeutics™ Development Program: Publication of Evidence for Oxysterols that Inhibit Hedgehog Signaling, a Tumorigenic Cellular Pathway MAX BioPharma, Inc. announced it has published the first evidence that...by Gonzalo Payan | Aug 9, 2015
In this new video, we introduce MAX BioPharma and how our use of Oxysterol Therapeutics can manage important diseases like Osteoporosis and Pancreatic Cancer....by Gonzalo Payan | Jul 21, 2015
Cutting-edge preclinical research carried out by California-based biotechnology startup MAX BioPharma is driving forward the development of novel therapeutics for orthopaedic procedures, osteoporosis and certain cancers...